This study is currently not recruiting participants.

402 Study: Trial of Assessing the Efficacy and Safety of ITI-007 Adjunctive to Lithium or Valproate in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression)

402 Study: Trial of Assessing the Efficacy and Safety of ITI-007 Adjunctive to Lithium or Valproate in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression)
Not Recruiting
18 years - 75 years
All
Phase 3
1 Location

Brief description of study

We are looking for people who are currently experiencing major depressive episodes associated with bipolar I or bipolar II disorder to take part in our bipolar depression studies. These clinical research studies are designed to help us learn more about an investigational medication for symptoms of bipolar depression.

Detailed description of study

The 402 study is a randomized, double-blind, placebo-controlled research study which is looking at whether an investigational medication, called ITI-007, can improve the symptoms of bipolar depression (bipolar I or bipolar II disorder). It also aims to look at how safe the investigational medication is and whether it impacts the quality of life and well-being of people with bipolar depression, when it is added to existing treatment with a mood stabilizer, specifically lithium or valproate.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Bipolar disorder,Depression,Major depression,Depression,depression
  • Age: 18 years - 75 years
  • Gender: All


Updated on 19 Feb 2024. Study ID: 824837

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.